Generic placeholder image

Current Cancer Drug Targets

Eiditor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

Fertility Drugs and Ovarian Cancer

Author(s): Aus Tariq Ali*

Volume 18 , Issue 6 , 2018

Published on: 20 June, 2017

Page: [567 - 576] Pages: 10

DOI: 10.2174/1568009617666170620102049

Price: $65

Abstract

The aetiology of ovarian cancer is multifactorial with both endogenous and exogenous risk factors playing an important role. The exact pathogenesis of ovarian cancer is still not well understood, despite the number of hypotheses published. Due to an increase in the number of women using fertility drugs, much attention has been focused on the long-term health effects of such drugs. Although fertility drugs facilitate the ovulation process, it is however associated with a significant increase in hormone concentrations, placing exposed women at increased risk of gynaecological cancer. Many clinical and epidemiological studies have examined the association between fertility drugs and ovarian cancer risk. Results from these studies have been contradictory, as some studies have reported an increased risk of ovarian cancer while others reported no increased risk. Nevertheless, recent studies have shown that women who used fertility drugs and did not conceive had a higher risk of developing ovarian cancer, compared to women who used fertility drugs and conceived and delivered successfully. This review discusses the effect of fertility drugs on the risk of developing ovarian cancer, providing details on four possible scenarios associated with fertility treatment. In addition, the limitations of previous studies and their impact on our understanding of the association between fertility drugs and ovarian cancer have also been highlighted.

Keywords: Ovulation, nulliparity, inflammation, oxidative stress, ovarian cancer, fertility drugs.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2021 Bentham Science Publishers | Privacy Policy